COMMUNIQUÉS West-GlobeNewswire

Arch Therapeutics Provided Corporate Update at the 11th Annual LD Micro Main Event
06/12/2018
Company highlighted US and EU regulatory filings and positive patent ruling in Japan FRAMINGHAM, Mass., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of [...]
Brain Scientific Announces Successful Commercialization & First Purchase Order Shipment Of NeuroCap
06/12/2018
NEW YORK, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Brain Scientific Inc. (OTC:BRSF) (“Brain Scientific” or “Company”), a medical device company combining brain analysis software with wireless sensor technologies for [...]
Auris Medical Announces Acquisition of Orphan Drug Designation and Secures Rights to In-License Additional Patents Related to Betahistine
06/12/2018
Acquires Orphan Drug Designation for betahistine for the treatment of obesity associated with Prader-Willi syndrome (PWS) Signs letter of intent to in-license two US patents covering use of betahistine for the treatment [...]
Pain Therapeutics Announces Initiation of a Phase II Study in Alzheimer’s Disease
06/12/2018
AUSTIN, Texas, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, announced today the initiation of a Phase II study to evaluate PTI-125 as a potential first line [...]
Meridian Gets FDA Clearance for New Neonatal Saliva CMV Test
06/12/2018
CINCINNATI, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that it has received FDA clearance for its new Alethia™ CMV Molecular Amplification Test (formerly, the illumi gene [...]
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data
06/12/2018
Positive interim analysis demonstrated proof-of-biology and proof-of-concept for BIIB067 Biogen plans to advance BIIB067 to a pivotal clinical study Biogen paid Ionis Pharmaceuticals a $35 million one-time upfront [...]
Tetra Bio-Pharma in Process of Filing Patent Application Exceeding its Data Protection Initial Assumption for its PPP001
06/12/2018
Company seeks to protect shareholders’ investments ORLEANS, Ontario, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc (“ Tetra ” or the “ Company ”) (TSX VENTURE: TBP) (OTCQB: TBPMF), a leader in cannabinoid-based [...]
iKang Schedules 2018 Unaudited Second Quarter Earnings Release on December 20, 2018
06/12/2018
BEIJING, Dec. 06, 2018 (GLOBE NEWSWIRE) -- iKang Healthcare Group, Inc. (“iKang” or the “Company”) (Nasdaq: KANG), a major provider in China’s fast growing private preventive healthcare services market, today announced [...]
FibroGen Appoints Maykin Ho, Ph.D., to Board of Directors
06/12/2018
SAN FRANCISCO, Dec. 06, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today announced the appointment [...]
Rule 2.9 Announcement
06/12/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 6 December 2018 [...]
GENFIT: Positive Phase 2 Results from Study of Elafibranor in Primary Biliary Cholangitis
06/12/2018
GENFIT: Positive Phase 2 Results from Study of Elafibranor in Primary Biliary Cholangitis Elafibranor successfully meets primary endpoint with high statistical significance of p<0.001 Substantial reductions in [...]
GENFIT : Résultats positifs de l'étude de Phase 2 évaluant elafibranor dans la Cholangite Biliaire Primitive (PBC)
06/12/2018
GENFIT : Résultats positifs de l'étude de Phase 2 évaluant elafibranor dans la Cholangite Biliaire Primitive (PBC) Elafibranor atteint avec succès le critère principal d'évaluation, avec une valeur statistique hautement [...]
ObsEva SA to Participate in BMO Healthcare Conference December 12, 2018
06/12/2018
Geneva, Switzerland and Boston, MA – December 6, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious [...]
Veloxis Increases Share Capital in Connection with Exercise of Warrants
06/12/2018
Company Release no. 20/2018 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 06 December 2018 Veloxis Increases Share Capital in Connection with Exercise of Warrants Veloxis Pharmaceuticals A/S announces that the Company' [...]
Teladoc Health Refutes SIRF Report Claims
06/12/2018
PURCHASE, NY, Dec. 05, 2018 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, is issuing the following statement in response to a report published today referencing an incident from [...]
IntelGenx Reports Amendment of Stock Option Plan
05/12/2018
SAINT LAURENT, Quebec, Dec. 05, 2018 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) reported today, that the Company's Board of Directors approved to amend the [...]
Optinose to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference
05/12/2018
YARDLEY, Pa., Dec. 05, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive [...]
Momenta Pharmaceuticals Announces Proposed Public Offering of Common Stock
05/12/2018
CAMBRIDGE, Mass., Dec. 05, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing novel therapeutics to [...]
Supernus Schedules Conference Call to Present Topline Results of Two Phase III Studies for SPN-812 in Children with ADHD
05/12/2018
ROCKVILLE, Md., Dec. 05, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system [...]

Pages